EFDID: 452220EFD: View Filing

Issuer: Areteia Therapeutics, Inc. (0001937542) - D

Accession: 0001937542-22-000001 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001937542
  • Entity Name:
    Areteia Therapeutics, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Within 5 years (2022)
  • Address:
    1200 MORRIS TURNPIKE
    SUITE 3005
    SHORT HILLS, NJ 07078
  • Persons:
    Related Persons 10
    Paul Berns
    Director
    Adam Koppel
    Director
    Ian Read
    Director
    Benjamin Gomez
    Director
    Michael E. Bozik
    Director
    Stephen Butts
    Director
    Jorge Bartolome
    Director
    Whit Bernard
    Executive Officer
    Chris Visioli
    Executive Officer
    Christopher Todd Cox
    Executive Officer
EDGAR: Offering Information
  • Accession Date:
    07/14/2022
  • First Sale Date:
    06/15/2022
  • Offering Amount:
    $350,000,000
  • Amount Sold:
    $175,000,000
  • Amount Remaining:
    $175,000,000
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
EFD: Current State Notices
View Notices

Notices found in EFD

Filed:CA, CT, MA, NJ, NY, TX
Inactive:IL
EDGAR: Sales Compensation Recipient Information

There were no Sales Compensation Recipient Information associated with this Accession Number.

EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Areteia Therapeutics, Inc./s/ Christopher Todd CoxChristopher Todd CoxGeneral Counsel2022-07-14
Related EDGAR Submissions
Type Edgar Date EFD: Accession
D/A Feb. 21, 2025 452220: 0001937542-25-000001 Areteia Therapeutics, Inc.
Offer Amount: $445,000,000
Amount Sold: $360,000,020
Remaining: $84,999,980
D/A Feb. 22, 2024 452220: 0001937542-24-000005 Areteia Therapeutics, Inc.
Offer Amount: $445,000,000
Amount Sold: $275,000,000
Remaining: $170,000,000
D Jul. 14, 2022 452220: 0001937542-22-000001 Areteia Therapeutics, Inc.
Offer Amount: $350,000,000
Amount Sold: $175,000,000
Remaining: $175,000,000